Add-On IVIG Improves Outcomes in New Idiopathic Inflammatory Myopathies

A double-blind, placebo-controlled randomized trial evaluated add-on IVIG versus placebo alongside high-dose prednisone in 44 adults newly diagnosed with idiopathic inflammatory myopathies. The trial reported significantly higher Total Improvement Scores at 12 weeks in the IVIG group (60.0 vs 42.5), with more patients achieving moderate and major improvement and reaching improvement faster; one asymptomatic deep venous thrombosis occurred in the IVIG group.

Most relevant for: Adult patients newly diagnosed with idiopathic inflammatory myopathies being treated with high-dose prednisone.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.